Northvale, NJ, March 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ADM Tronics Unlimited, Inc. (OTCQB – ADMT) announced today that it will be participating at the Lytham Partners Spring 2021 Investor Conference. Andre DiMino, President of ADMT, will be available for virtual one-on-one meetings throughout the event, which runs from March 30, 2021 through April 1, 2021. To arrange a meeting, contact Lytham Partners at: 1x1@lythampartners.com or register here: Register (meetmax.com).
“We are pleased to participate in this year’s Lytham Partners Investor Spring Conference and for the opportunity to discuss our company’s progress with our innovative medical technologies currently in development,” stated DiMino.
ADMT specializes in design, development and manufacturing of diagnostic and therapeutic electronic medical technologies at its FDA-Registered and ISO-13485 Certified Medical Device Manufacturing Facility in Northvale, NJ. ADMT has extensive experience in the development of all FDA classes of medical devices with particular emphasis on electronic therapeutic modalities. The Company has a pipeline of several proprietary medical devices currently in various stages of development.
In addition to its own medical technology developments, the Company is a one-stop source for complete design, engineering, regulatory and manufacturing services, specifically related to US and international medical device development. Its capability in bringing a medical device from the conceptual stage, through design, development and regulatory stages into production, all in-house, differentiates ADMT from firms supplying only portions of those services. ADMT welcomes inquiries for its medical device services via the ADMT website – www.admtronics.com.
To receive email updates directly from the Company, fill in the form at the bottom of this page: https://admtronics.com/investor-relations/
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Medical Devices; Medical Device Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly Formulations from its headquarters, laboratories, and FDA-Registered medical device manufacturing operations. ADMT’s multi-disciplinary team of engineers, researchers, and technologists utilize advanced technology infrastructure for R&D and commercialization of diversified technologies. admtronics.com.
Except for historical information contained herein, the matters set forth in this news release are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT’s SEC filings, news releases, and other communications. The Company assumes no obligation to update the information contained in this news release.
Press Contact– Andre’ DiMino – 201-767-6040 – andre@admtronics.com
